Philip J. Campbell is a Hematologist-Oncologist based in Geelong, VIC, Australia. He works with people who have conditions that affect the blood, the bone marrow, and the lymph system. That can look very different from one person to the next, so appointments usually start with listening closely and making a clear plan.
In day-to-day practice, Philip looks after patients with cancers of the blood and lymph system, including multiple myeloma, non-Hodgkin lymphomas, and leukaemias. This includes long-term blood cancers such as chronic lymphocytic leukaemia (CLL) and chronic B-cell leukaemia (CBCL), as well as other lymphoma types like follicular lymphoma. At times, patients also need help with more complex situations such as Richter syndrome, where a lymphoma becomes more aggressive.
He also treats people with blood clot issues. That might be related to conditions like blood clots and can overlap with other blood problems. Another part of his work involves platelet and bleeding concerns, including thrombocytopenia (low platelets) and purpura, which can show up as bruising or red or purple spots on the skin.
For some patients, treatment may involve specialist procedures such as a bone marrow transplant. Where that’s being considered, the process can feel overwhelming. Philip focuses on explaining what’s happening, what to expect, and how the treatment fits with the person’s overall health.
Some patients also come to him after a splenectomy (removal of the spleen), including those dealing with post-splenectomy syndrome. The goal is to manage the risks that can come with loss of spleen function, and to keep care organised and practical.
In many cases, care also needs a careful long-term approach. Philip works with the wider health team so treatment can be coordinated when people need tests, scans, medicines, or follow-up visits. Over time, that ongoing support matters, especially when symptoms change or treatment plans need adjusting.
Where relevant, Philip may also discuss clinical trial options. Clinical trials can offer access to new treatments, but whether they’re a good fit depends on the person’s situation, test results, and timing. He takes the time to talk through options in plain language, not rushing decisions.
